SOBA-AD

About AltPep

AltPep is pioneering a novel approach to amyloid diseases by targeting the toxic soluble oligomers that form early in disease progression, rather than the later-stage plaques. Founded in 2018 on decades of academic research from the University of Washington, the company has built a dual-purpose platform for both diagnostics (SOBA) and therapeutics (SOBIN). Its lead programs are in preclinical development for Alzheimer's and Parkinson's diseases, aiming to enable pre-symptomatic intervention in a market affecting over a billion people globally. The company is led by its founder and CEO, Dr. Valerie Daggett, who discovered the foundational α-sheet structure.

Therapeutic Areas

Other Alzheimer's Disease Detection Drugs